Krebs Biochemicals Industries Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Krebs Biochemicals & Industries Ltd is ₹ 58.92 as of 04 May 10:16 . The P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 174.33 crore on March 2021 to ₹ 144 crore on March 2025 . This represents a CAGR of -3.75% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 years The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 7.28 crore as compare to the Sep '25 revenue of ₹ 4.17 crore. This represent the growth of 74.58% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 4.33 crore as compare to the Sep '25 revenue of ₹ 2.54 crore. This represent the growth of 70.47% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0.3 crore as compare to the Sep '25 ebitda of ₹ -2.79 crore. This represent the decline of -110% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ -0.19 crore as compare to the Sep '25 ebitda of ₹ -1.58 crore. This represent the decline of -87.97% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ -5.17 crore to ₹ -3.13 crore over 7 quarters. This represents a CAGR of -24.93% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ -0.73 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.

About Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Krebs Biochemicals & Industries Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Krebs Biochemicals & Industries Ltd or Parmax Pharma Ltd?

Market cap of Krebs Biochemicals & Industries Ltd is 129 Cr while Market cap of Parmax Pharma Ltd is 11 Cr

What are the key factors driving the stock performance of Krebs Biochemicals & Industries Ltd and Parmax Pharma Ltd?

The stock performance of Krebs Biochemicals & Industries Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Krebs Biochemicals & Industries Ltd and Parmax Pharma Ltd?

As of May 4, 2026, the Krebs Biochemicals & Industries Ltd stock price is INR ₹60.12. On the other hand, Parmax Pharma Ltd stock price is INR ₹30.02.

How do dividend payouts of Krebs Biochemicals & Industries Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Krebs Biochemicals & Industries Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.